20/10/2026
What if access to treatment wasn’t limited by cost, but by how we choose to organise our healthcare systems?
Biosimilars are challenging that reality. By reducing the cost of biological treatments without compromising safety, quality, or effectiveness, they create space for healthcare systems to treat more patients and start therapies earlier.
But their impact goes beyond savings. They raise an important question: how do we translate financial efficiency into real equity, ensuring that patients, regardless of where they live, can access the care they need?
As healthcare budgets come under increasing pressure, biosimilars are not just an alternative; they test how we prioritise sustainability, fairness, and access in modern healthcare.